
Sign up to save your podcasts
Or


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic cancer, and the implications of this process on treatment recommendations.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic cancer, and the implications of this process on treatment recommendations.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a description of the magnitude of the impact of pancreatic cancer in the US.
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a description of the magnitude of the impact of pancreatic cancer in the US.
Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.
Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years.
Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.
From the publisher's feed

2 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners